Compare Crispr Therapeutics AG (CRSP) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rush Street Interactive Inc — how do they compare? Crispr Therapeutics AG trades at $50.48 (market cap $4.97B), while Rush Street Interactive Inc trades at $33.75 (market cap $3.45B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | RSI | |
|---|---|---|
Market Cap | $4.97B | $3.45B |
Sector | Health | Technology |
52-Week High | $76.78 | $34.18 |
52-Week Low | $44.34 | $14.51 |
Enterprise Value | $3.32B | $3.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
RSI stock trades at $34.18, up 2.34% today, with a bullish technical signal from moving averages and strong institutional support. Recent Q1 2026 earnings beat expectations with EPS of $0.14 versus $0.12 expected, while revenue grew to $1.13B in 2025. The company expanded into Alberta with BetRivers launch, enhancing its online gaming footprint.
Outlook remains positive with 76.9% analyst buy ratings and a consensus price target of $29.44, though high valuation multiples (P/E 98.56) and overbought RSI levels near 77.56 pose near-term risks. Key catalysts include Q2 2026 earnings on July 29, 2026, and execution of the $100M share repurchase program.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
